BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23457377)

  • 1. Agreement between the DAS28-CRP assessed with 3 and 4 variables in patients with rheumatoid arthritis treated with biological agents in the daily clinic.
    Madsen OR
    J Rheumatol; 2013 Apr; 40(4):379-85. PubMed ID: 23457377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is DAS28-CRP with three and four variables interchangeable in individual patients selected for biological treatment in daily clinical practice?
    Madsen OR
    Clin Rheumatol; 2011 Dec; 30(12):1577-82. PubMed ID: 21956233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
    Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the DAS28-CRP and DAS28-ESR in patients with rheumatoid arthritis.
    Sengul I; Akcay-Yalbuzdag S; Ince B; Goksel-Karatepe A; Kaya T
    Int J Rheum Dis; 2015 Jul; 18(6):640-5. PubMed ID: 26013310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers.
    Chandrashekara S; Priyanka BU
    Int J Rheum Dis; 2013 Jun; 16(3):291-6. PubMed ID: 23981750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gain in quality-adjusted life-years in patients with rheumatoid arthritis during 1 year of biological therapy: a prospective study in clinical practice.
    Linde L; Sørensen J; Østergaard M; Hetland ML
    J Rheumatol; 2013 Sep; 40(9):1479-86. PubMed ID: 23818719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of clinical outcome measures in rheumatoid arthritis patients with stable disease defined on the basis of the EULAR response criteria.
    Madsen OR
    Clin Rheumatol; 2016 Oct; 35(10):2403-9. PubMed ID: 27283868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.
    Aletaha D; Nell VP; Stamm T; Uffmann M; Pflugbeil S; Machold K; Smolen JS
    Arthritis Res Ther; 2005; 7(4):R796-806. PubMed ID: 15987481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which variables best predict change in rheumatoid arthritis therapy in daily clinical practice?
    Soubrier M; Zerkak D; Gossec L; Ayral X; Roux C; Dougados M
    J Rheumatol; 2006 Jul; 33(7):1243-6. PubMed ID: 16622906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.
    Inoue E; Yamanaka H; Hara M; Tomatsu T; Kamatani N
    Ann Rheum Dis; 2007 Mar; 66(3):407-9. PubMed ID: 16926186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can remission in rheumatoid arthritis be assessed without laboratory tests or a formal joint count? possible remission criteria based on a self-report RAPID3 score and careful joint examination in the ESPOIR cohort.
    Castrejón I; Dougados M; Combe B; Guillemin F; Fautrel B; Pincus T
    J Rheumatol; 2013 Apr; 40(4):386-93. PubMed ID: 23378463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis.
    Wolbink GJ; Voskuyl AE; Lems WF; de Groot E; Nurmohamed MT; Tak PP; Dijkmans BA; Aarden L
    Ann Rheum Dis; 2005 May; 64(5):704-7. PubMed ID: 15485995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis.
    Wiacek R; Kolossa K; Jankowski T; Jeka S; Karmowski A; Karmowski M; Gworys B
    Adv Clin Exp Med; 2012; 21(3):337-42. PubMed ID: 23214197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-derived joint counts are a potential alternative for determining Disease Activity Score.
    Kavanaugh A; Lee SJ; Weng HH; Chon Y; Huang XY; Lin SL
    J Rheumatol; 2010 May; 37(5):1035-41. PubMed ID: 20156946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T; Furer V; Keystone E; Yazici Y; Bergman MJ; Luijtens K
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.